Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
They should not go in a normal bin or be reused
With the possibility of complications, users should consume Semaglutide under medical supervision
Unless and until large, well-designed human trials clarify safety and efficacy, BPC-157 remains an unapproved peptide, subject to regulatory controls and compliance requirements in drug-tested populations
Reported benefits (per available research): Studied for restoring more youthful pulsatile GH and IGF-1 secretion in older adults, based on a small 1997 randomized, placebo-controlled human trial of a closely related GHRH(1-29) analog published in the Journal of Clinical Endocrinology & Metabolism May support gains in lean body mass in men specifically: that same 16-week trial found a statistically significant increase in lean body mass in men but not in women, alongside a significant increase in skin thickness (a marker of dermal collagen) in both sexes Proposed to support broader recovery and body-composition goals tied to growth-hormone-axis activity, though sermorelin-specific modern adult trial data remains thin, and much of the anti-aging and muscle-building framing used in commercial marketing outpaces the current clinical evidence base Known risks and side effects: Injection-site reactions (pain, swelling, or redness) are the most commonly reported adverse event associated with sermorelin therapy in manufacturer drug-labeling data Headache, flushing, dizziness, difficulty swallowing, hyperactivity, drowsiness, and hives have also been reported less commonly per that same labeling data
Nine patients in seven families have been reported worldwide (USA, Germany, Japan, The Netherlands, Poland, and Spain)
